Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR

Cited 12 time in webofscience Cited 0 time in scopus
  • Hit : 341
  • Download : 0
Deregulation of EGFR is involved in the development of many cancers. The inhibition of EGFR kinase activity has been clinically validated as a promising approach for the treatment of non-small-cell lung cancer (NSCLC). However, all NSCLC patients who initially benefited from first-generation EGFR inhibitors eventually develop drug resistance. A point mutation at the gatekeeper position, T790M in EGFR kinase domain accounts for more than 50% of acquired resistance. Therefore, second-and third-generation EGFR inhibitors have been developed to overcome the resistance conferred by the gatekeeper mutation. This review has highlighted recent advances in overcoming acquired resistance for the development of each generation of EGFR inhibitors along with their potential issues, and urgent quest for the development of new generation of EGFR inhibitors
Publisher
FUTURE SCI LTD
Issue Date
2016-05
Language
English
Article Type
Review
Citation

FUTURE MEDICINAL CHEMISTRY, v.8, no.8, pp.853 - 878

ISSN
1756-8919
DOI
10.4155/fmc-2016-0019
URI
http://hdl.handle.net/10203/212153
Appears in Collection
CH-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 12 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0